Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene pays $177 million for cancer stem cell pact with OncoMed

This article was originally published in Scrip

Executive Summary

Celgene is making a bet on therapies that target cancer stem cells, paying more than $177 million to potentially license experimental treatments from newly public biotech OncoMed Pharmaceuticals.

You may also be interested in...



OncoMed Loses Another Asset – Rosmantuzumab – And CEO Paul Hastings

Loss of anti-RSPO-3 antibody rosmantuzumab, partnered with Celgene, means a rough start to the year, following disappointments in 2017.

Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash

OncoMed lays off half its employees after a series of recent clinical setbacks. Meanwhile, six public companies raise $1.64bn in $100m-plus follow-on and debt offerings, SV Health Investors closed a $400m venture capital fund and eight therapeutics firms grabbed $247.5m in VC cash.

Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs

Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.

Topics

Related Companies

UsernamePublicRestriction

Register

SC023664

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel